학술논문
Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort.
Document Type
Academic Journal
Author
Wong K; National Registry of Rare Kidney Diseases, Bristol, UK; Department of Renal Medicine, University College London, London, UK.; Pitcher D; National Registry of Rare Kidney Diseases, Bristol, UK.; Braddon F; National Registry of Rare Kidney Diseases, Bristol, UK.; Downward L; National Registry of Rare Kidney Diseases, Bristol, UK.; Steenkamp R; UK Renal Registry, Bristol, UK.; Annear N; Institute of Medical and Biomedical Education, St George's University of London, London, UK.; Barratt J; Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.; Bingham C; University of Exeter Medical School, University of Exeter, Exeter, UK.; Chrysochou C; Division of Cardiovascular Sciences, University of Manchester, Manchester, UK.; Coward RJ; Translational Health Sciences, University of Bristol, Bristol, UK.; Game D; Guy's and St Thomas' NHS Foundation Trust, London, UK.; Griffin S; Department of Nephrology, University Hospital Wales, Cardiff, UK.; Hall M; Nottingham Renal and Transplant Unit, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK.; Johnson S; Great North Children's Hospital, Newcastle upon Tyne, UK.; Kanigicherla D; Division of Cardiovascular Sciences, University of Manchester, Manchester, UK.; Karet Frankl F; Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.; Kavanagh D; National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; Complement Therapeutics Research Group, Newcastle University, Newcastle upon Tyne, UK; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.; Kerecuk L; Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.; Maher ER; Department of Medical Genetics, University of Cambridge, Cambridge, UK.; Moochhala S; Department of Renal Medicine, Royal Free London NHS Foundation Trust, London, UK.; Pinney J; Department of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Sayer JA; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.; Simms R; Academic Unit of Nephrology, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.; Sinha S; Division of Cardiovascular Sciences, University of Manchester, Manchester, UK; Department of Renal Medicine, Northern Care Alliance NHS Foundation Trust, Manchester, UK.; Srivastava S; Department of Renal Medicine, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK.; Tam FWK; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, UK.; Turner AN; Medical Research Council Centre for Inflammation, Edinburgh University, Edinburgh, UK.; Walsh SB; Department of Renal Medicine, University College London, London, UK; Department of Renal Medicine, Royal Free London NHS Foundation Trust, London, UK.; Waters A; Department of Paediatrics and Child Health, University College Cork, Cork, Ireland.; Wilson P; Department of Renal Medicine, University College London, London, UK.; Wong E; National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.; Taylor CM; Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.; Nitsch D; UK Renal Registry, Bristol, UK; London School of Hygiene and Tropical Medicine, London, UK.; Saleem M; Translational Health Sciences, University of Bristol, Bristol, UK.; Bockenhauer D; Department of Renal Medicine, University College London, London, UK; Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.; Bramham K; National Registry of Rare Kidney Diseases, Bristol, UK; King's Health Partners, King's College London, London, UK.; Gale DP; National Registry of Rare Kidney Diseases, Bristol, UK; Department of Renal Medicine, University College London, London, UK; Department of Renal Medicine, Royal Free London NHS Foundation Trust, London, UK. Electronic address: d.gale@ucl.ac.uk.
Source
Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Individuals with rare kidney diseases account for 5-10% of people with chronic kidney disease, but constitute more than 25% of patients receiving kidney replacement therapy. The National Registry of Rare Kidney Diseases (RaDaR) gathers longitudinal data from patients with these conditions, which we used to study disease progression and outcomes of death and kidney failure.
Methods: People aged 0-96 years living with 28 types of rare kidney diseases were recruited from 108 UK renal care facilities. The primary outcomes were cumulative incidence of mortality and kidney failure in individuals with rare kidney diseases, which were calculated and compared with that of unselected patients with chronic kidney disease. Cumulative incidence and Kaplan-Meier survival estimates were calculated for the following outcomes: median age at kidney failure; median age at death; time from start of dialysis to death; and time from diagnosis to estimated glomerular filtration rate (eGFR) thresholds, allowing calculation of time from last eGFR of 75 mL/min per 1·73 m2 or more to first eGFR of less than 30 mL/min per 1·73 m 2 (the therapeutic trial window).
Findings: Between Jan 18, 2010, and July 25, 2022, 27 285 participants were recruited to RaDaR. Median follow-up time from diagnosis was 9·6 years (IQR 5·9-16·7). RaDaR participants had significantly higher 5-year cumulative incidence of kidney failure than 2·81 million UK patients with all-cause chronic kidney disease (28% vs 1%; p<0·0001), but better survival rates (standardised mortality ratio 0·42 [95% CI 0·32-0·52]; p<0·0001). Median age at kidney failure, median age at death, time from start of dialysis to death, time from diagnosis to eGFR thresholds, and therapeutic trial window all varied substantially between rare diseases.
Interpretation: Patients with rare kidney diseases differ from the general population of individuals with chronic kidney disease: they have higher 5-year rates of kidney failure but higher survival than other patients with chronic kidney disease stages 3-5, and so are over-represented in the cohort of patients requiring kidney replacement therapy. Addressing unmet therapeutic need for patients with rare kidney diseases could have a large beneficial effect on long-term kidney replacement therapy demand.
Funding: RaDaR is funded by the Medical Research Council, Kidney Research UK, Kidney Care UK, and the Polycystic Kidney Disease Charity.
Competing Interests: Declaration of interests ERM reports support for the current manuscript from VHL UK/Ireland and consulting fees from MSD. SM is chair of OxalEurope. MS reports support for the current manuscript from a Medical Research Council UK Precision Medicine programme grant (MR/R013942/1) and consulting fees from Travere Therapeutics. RJC reports support for the current manuscript from Kidney Research UK. JAS reports support for the current manuscript from Kidney Research UK, Northern Counties Kidney Research Fund, and the Medical Research Council UK (all payments to institution). JAS is Academic Vice President of the UK Kidney Association. FWKT reports support from the National Institute for Health and Care Research Imperial Biomedical Centre. DN is the UK Kidney Association Director of Informatics Research. DPG reports support for the current manuscript from St Peter's Trust for Kidney Bladder and Prostate Research, Medical Research Council, Kidney Research UK, Kidney Care UK, and Polycystic Kidney Disease Charity (all payments to institution). DPG chairs the Rare Diseases Committee of the UK Kidney Association and reports fees for consulting and presenting from Novartis, Alexion, Calliditas, Sanofi, Britannia, and Travere. All other authors declare no competing interests.
(Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
Methods: People aged 0-96 years living with 28 types of rare kidney diseases were recruited from 108 UK renal care facilities. The primary outcomes were cumulative incidence of mortality and kidney failure in individuals with rare kidney diseases, which were calculated and compared with that of unselected patients with chronic kidney disease. Cumulative incidence and Kaplan-Meier survival estimates were calculated for the following outcomes: median age at kidney failure; median age at death; time from start of dialysis to death; and time from diagnosis to estimated glomerular filtration rate (eGFR) thresholds, allowing calculation of time from last eGFR of 75 mL/min per 1·73 m
Findings: Between Jan 18, 2010, and July 25, 2022, 27 285 participants were recruited to RaDaR. Median follow-up time from diagnosis was 9·6 years (IQR 5·9-16·7). RaDaR participants had significantly higher 5-year cumulative incidence of kidney failure than 2·81 million UK patients with all-cause chronic kidney disease (28% vs 1%; p<0·0001), but better survival rates (standardised mortality ratio 0·42 [95% CI 0·32-0·52]; p<0·0001). Median age at kidney failure, median age at death, time from start of dialysis to death, time from diagnosis to eGFR thresholds, and therapeutic trial window all varied substantially between rare diseases.
Interpretation: Patients with rare kidney diseases differ from the general population of individuals with chronic kidney disease: they have higher 5-year rates of kidney failure but higher survival than other patients with chronic kidney disease stages 3-5, and so are over-represented in the cohort of patients requiring kidney replacement therapy. Addressing unmet therapeutic need for patients with rare kidney diseases could have a large beneficial effect on long-term kidney replacement therapy demand.
Funding: RaDaR is funded by the Medical Research Council, Kidney Research UK, Kidney Care UK, and the Polycystic Kidney Disease Charity.
Competing Interests: Declaration of interests ERM reports support for the current manuscript from VHL UK/Ireland and consulting fees from MSD. SM is chair of OxalEurope. MS reports support for the current manuscript from a Medical Research Council UK Precision Medicine programme grant (MR/R013942/1) and consulting fees from Travere Therapeutics. RJC reports support for the current manuscript from Kidney Research UK. JAS reports support for the current manuscript from Kidney Research UK, Northern Counties Kidney Research Fund, and the Medical Research Council UK (all payments to institution). JAS is Academic Vice President of the UK Kidney Association. FWKT reports support from the National Institute for Health and Care Research Imperial Biomedical Centre. DN is the UK Kidney Association Director of Informatics Research. DPG reports support for the current manuscript from St Peter's Trust for Kidney Bladder and Prostate Research, Medical Research Council, Kidney Research UK, Kidney Care UK, and Polycystic Kidney Disease Charity (all payments to institution). DPG chairs the Rare Diseases Committee of the UK Kidney Association and reports fees for consulting and presenting from Novartis, Alexion, Calliditas, Sanofi, Britannia, and Travere. All other authors declare no competing interests.
(Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)